Fasenra
AstraZeneca’s Fasenra has strong Phase 3 showing in severe eosinophilic asthma
August 6, 2020Research and Development AstraZeneca, Fasenra, asthma
AstraZeneca took the opportunity at the American Thoracic Society 2020 Virtual International Conference to unveil positive new Phase 3b data …
FDA approves single-use auto-injector form of IL-5 inhibitor Fasenra
October 4, 2019Medical Communications, Sales and Marketing AstraZeneca, FDA, Fasenra, pharma
AstraZeneca is celebrating as the FDA announced the approval of its IL-5 inhibitor Fasenra (benralizumab) in a pre-filled, single-use auto-injector …
AstraZeneca’s early-stage Fasenra study smashes primary endpoint in hypereosinophilic syndrome
April 4, 2019Research and Development AstraZeneca, Fasenra, hypereosinophilic syndrome, pharma
AstraZeneca has revealed new data for Fasenra (benralizumab), demonstrating that patients using the drug can “achieve near-complete depletion of eosinophils …
NICE recommends AstraZeneca’s Fasenra as third treatment option for severe asthma
January 4, 2019Medical Communications, Sales and Marketing AstraZeneca, Fasenra, NHS, NICE, UK, asthma, pharma
It’s good news for both asthma patients and AstraZeneca after UK drug watchdog NICE saw fit to recommend the drugmaker’s …
AZ’s hopes for Fasenra in COPD suffer terminal blow
May 30, 2018Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical
It looked unlikely that Fasenra would achieve success in the chronic obstructive pulmonary disease (COPD) area, after it suffered in …
AZ’s Fasenra stumbles in P3 for COPD
May 11, 2018Medical Communications, Research and Development AstraZeneca, Fasenra, GSK, Nucala, biotech, drugs, pharma, pharmaceutical
AstraZeneca’s Fasenra arrived later on the scene than GSK rival med, Nucala, and so it needed to quickly rack up …
AstraZeneca scores double approvals in Japan for asthma and ovarian cancer
January 19, 2018Medical Communications, Sales and Marketing AstraZeneca, Cancer, Fasenra, Japan, asthma, lynparza, ovarian cancer, pharma
AstraZeneca has unveiled a double dose of approvals awarded to its medicines in Japan: Fasenra (benralizumab) has been given authorisation …
AZ’s Fasenra approved in Europe as an add-on for severe eosinophilic asthma
January 11, 2018Research and Development AstraZeneca, European Commission, Fasenra, MedImmune, asthma, pharma
AstraZeneca and its biologics R&D unit MedImmune have announced that their drug Fasenra (benralizumab) has received approval from the European …
AstraZeneca’s Fasenra scores US approval in severe asthma
November 15, 2017Research and Development, Sales and Marketing AstraZeneca, Fasenra, MedImmune, asthma
AstraZeneca and MedImmune, the company’s biologics research and development division, have revealed the decision by the FDA to approve Fasenra …
Latest content
Five Facts about cardiovascular disease
